|
|
|
|
|||||
|
|
|
Tectonic Therapeutic, Inc. (NASDAQ:TECX) is one of the Best Micro-Cap Stocks to Invest in According to Analysts.
On November 18, LifeSci Capital reiterated a Buy rating on Tectonic Therapeutic, Inc. (NASDAQ:TECX) stock with a price target of $88. Tectonic Therapeutic, Inc. (NASDAQ:TECX) is a biotechnology company that focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors.
Tectonic Therapeutic, Inc. (NASDAQ:TECX) develops the GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. One of the lead product candidates of the firm is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia, a GPCR modulator bispecific for treating fibrosis, and other GPCR modulators.
While we acknowledge the potential of TECX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Dividend Stocks Paying 4%+ Yield in 2025 and 14 Best US Stocks to Buy for Long Term
Disclosure: None.| Dec-10 | |
| Dec-01 | |
| Nov-06 | |
| Oct-29 | |
| Aug-28 | |
| Aug-07 | |
| Jun-30 | |
| Jun-24 | |
| May-17 | |
| May-13 | |
| May-08 | |
| May-07 | |
| May-01 | |
| Apr-23 | |
| Apr-15 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite